It should also be noted that the patients who exhibited the best responses had received monthly adjuvant IFN-β therapy prior to melanoma metastasis, so it is possible that pre-treatment with IFN-β might also enhance the anti-tumor effects of nivolumab. This evidence concerns the gene IFNB1 and melanoma.